EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS AS COMPARED TO GP2017 (ADALIMUMAB BIOSIMILAR
- Conditions
- M45-M45
- Registration Number
- PER-008-18
- Lead Sponsor
- OVARTIS BIOSCIENSES PERU S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 35
1. Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed
2. Male or non-pregnant, non-lactating female patients at least 18 years of age
3. Diagnosis of moderate to severe AS with radiologic evidence (centrally read X-ray) fulfilling the Modified New York criteria for AS (Appendix 3)
4. Active AS assessed by total BASDAI ≥ 4 (0-10) at Baseline
5. Spinal pain as measured by BASDAI question #2 ≥ 4 (0-10) at Baseline
6. Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline
1. Pacientes con anquilosis total de la columna vertebral.
2. Radiografia de torax o RM de torax con evidencia de un proceso infeccioso o maligno en curso, que se deben obtener en un plazo de 3 meses antes de la seleccion y deben ser evaluadas por un medico calificado.
3. Exposicion previa al secukinumab, al adalimumab o a cualquier otro agente biologico inmunomodulador, incluidos los dirigidos a la IL-17, al receptor de IL-17 o al TNFα.
4. Pacientes que tomen analgesicos opioides de alta potencia (p. ej., metadona, hidromorfona, morfina y oxicodona).
5. Uso de dispositivos o farmacos en investigacion dentro de las 4 semanas de la aleatorizacion o un periodo de 5 vidas medias del farmaco en investigacion, lo que sea mas prolongado.
6. Antecedentes de hipersensibilidad a cualquiera de los farmacos del estudio o a farmacos de clases quimicas similares.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method